284A Sharma, Manish - Thomas Jefferson University - Thomas Jefferson University

Manish Sharma, MD

Contact Dr. Sharma

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Taking a Measured Approach to Toxicity Data in Phase i Oncology Clinical Trials
  2. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials
  3. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer
  4. Reverse warburg effect in a patient with aggressive B-cell lymphoma: Is lactic acidosis a paraneoplastic syndrome?
  5. Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
  6. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients
  7. Estimation of renal cell carcinoma treatment effects from disease progression modeling
  8. Models of excellence: Improving oncology drug development
  9. Why RECIST works and why it should stay--reply to counterpoint.
  10. Why RECIST works and why it should stay - Counterpoint
  11. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox - Point/Counterpoint
  12. Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the University of Chicago Phase II Consortium
  13. Resampling phase III data to assess phase II Trial designs and endpoints
  14. Role of randomized phase III trials in an era of effective targeted therapies
  15. Randomized phase II Trials: A long-term investment with promising returns
  16. A phase i study of sirolimus and bevacizumab in patients with advanced malignancies
  17. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy
  18. Other paradigms: Better treatments are identified by better trials: The value of randomized phase II studies
  19. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab
  20. DNA repair genes, electromagnetic fields and susceptibility to acute leukemia?